Here is why Biogen Inc. (BIIB) stock tumbled in the after-hours on Tuesday?

Biogen Inc. (BIIB) shares plunged 7.62% in after-hours on Tuesday, January 12, 2022, and closed the daily trading at $223.12. However, in the regular trading session, BIIB’s stock gained 2.64%. BIIB shares have fallen 9.68% over the last 12 months, and they have moved down 0.09% in the past week. Over the past three months, the stock has lost 15.19%, while over the past six months, it has declined 31.40%.

Let’s discuss its recent news & developments.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

>> 7 Top Picks for the Post-Pandemic Economy << 

Another obstacle to BIIB Alzheimer’s drug

On January 11, 2021, U.S. regulators severely limited which patients can access the controversial BIIB Alzheimer’s treatment, Aduhelm.

Read More

The Centers for Medicare and Medicaid Services announced that it would cover the cost of treatment for patients enrolled in clinical studies but the Biogen has to prove to remove that plaque, called amyloid, leads to a benefit on cognition.

A Biogen spokesperson said that this will exclude almost all patients who may benefit and will significantly limit patient access to an FDA-approved treatment, especially for underserved patients.

Aduhelm was approved by the U.S. Food and Drug Administration in June last year via a path called accelerated approval.

BIIB to host an analytical call

Biogen Inc.  (BIIB) will host an analyst Q&A call on Thursday, January 13, 2022, at 8:00 a.m. ET. To access the live webcast, please visit the Investors section of Biogen’s website at

Participation in the recent event

Biogen Inc.  (BIIB) recently participated at the 40th Annual J.P. Morgan Healthcare Conference. Which was held on Monday, January 10, 2022.

BIIB license to commercialize BIIB115/ION306

On January 04, 2022, Biogen Inc. (BIIB) exercised its option to obtain from Ionis Pharmaceuticals a worldwide, exclusive, royalty-bearing license to develop and commercialize BIIB115/ION306.

Both companies have a strategic collaboration to develop novel therapies to treat neurological disorders. BIIB115 is an investigational antisense oligonucleotide (ASO) in development for spinal muscular atrophy (SMA) that may have the potential to help address additional unmet needs of patients as well as to be administered at extended dosing intervals.

Fast track designation for BIIB Lecanemab

On December 23, 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to Lecanemab, which is an investigational anti-amyloid beta (Aβ) protofibril antibody for the treatment of early Alzheimer’s disease.

Lecanemab is under development by Biogen (BIIB) and Eisai Co., Ltd. In September 2021, Eisai initiated a rolling submission to the FDA of a Biologics License Application (BLA) for lecanemab under the accelerated approval pathway and FDA granted Breakthrough Therapy designation in June of 2021.

>> 7 Top Picks for the Post-Pandemic Economy << 


The recent limitation for Biogen’s Aduhelm was the reason behind its after-hours sinking on Tuesday. We can expect it to continue to decline on Wednesday as well.

Most Popular

Related posts